NSE: GLENMARK | BSE: 532296

Mid-range Performer

Download real time

2004.40 85.60 (4.46%)

57.15% Gain from 52W Low

1.4M NSE+BSE Volume

NSE 03 Sep, 2025 3:31 PM (IST)

56,564.3

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Product Launch

Glenmark to launch bioequivalent of Eisai's Halaven injection in US, with annual sales of $66.3 mn See details

Glenmark Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLENMARK, BSE:532296 Glenmark Pharmaceuticals Ltd.

Search Inside the pdf :

Glenmark Pharmaceuticals Ltd.

02 Sep 2025, 12:00AM

2004.40

4.46%

Growth momentum and margin stability expected from H2FY26E

Buy: Glenmark Pharmaceuticals Ltd.

Target

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by -1.1 %/+13.2%, respectively, as we factor in improvement in EBITDA margins on account of improving mix and launch of high margin products.

Glenmark Pharmaceuticals Ltd. is trading below its 30 day SMA of 2033.4

Glenmark Pharmaceuticals Ltd.

19 Aug 2025

2004.40

4.46%

Base biz struggle continues; ISB 2001 deal holds valuation

Sell: Glenmark Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Glenmark Pharmaceuticals’ (Glenmark) Q1FY26 performance was below our expectation due to muted show across regions. Rise in other operating income inflated margins and PAT.

Number of FII/FPI investors decreased from 404 to 396 in Jun 2025 qtr

Glenmark Pharmaceuticals Ltd.

18 Aug 2025

2004.40

4.46%

Weak 1QFY26 performance

Buy: Glenmark Pharmaceuticals Ltd.

Target

Motilal Oswal

Glenmark Pharma (GNP) reported a lower-than-expected performance in 1QFY26, as revenue/EBITDA/PAT came in 9%/14%/15% below our estimates.

Glenmark Pharmaceuticals Ltd. has gained 33.85% in the last 3 Months

Glenmark Pharmaceuticals Ltd.

18 Jul 2025

2004.40

4.46%

ISB 2001 deal well-done; valuation defies uncertainties ahead

Sell: Glenmark Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Glenmark Pharmaceuticals’ (Glenmark) subsidiary Ichnos Glenmark Innovation (IGI) has out-licensed its oncology asset ISB 2001 to Abbvie in a deal valued at USD 1.925bn, including USD 700mn upfront, USD 1.225bn in milestones and tiered doubledigit royalty on net sales.

Glenmark Pharmaceuticals Ltd. is trading below its 30 day SMA of 2033.4

Glenmark Pharmaceuticals Ltd.

11 Jul 2025

2004.40

4.46%

Stock Flash

Buy: Glenmark Pharmaceuticals Ltd.

Deven Choksey

Ichnos Glenmark Innovation (IGI), a wholly-owned subsidiary of Glenmark
Pharmaceuticals, has entered into an exclusive global licensing agreement
with AbbVie for the development and commercialization of IGI’s lead
oncology asset, ISB 2001. This first-in-class CD38×BCMA×CD3 trispecific
antibody is currently in Phase 1 clinical trials for relapsed/refractory multiple
myeloma (R/R MM).

Glenmark Pharmaceuticals Ltd. is trading below its 30 day SMA of 2033.4

Glenmark Pharmaceuticals Ltd.

11 Jul 2025

2004.40

4.46%

Innovation validated; blockbuster potential unfolds

Buy: Glenmark Pharmaceuticals Ltd.

Target

Motilal Oswal

AbbVie partnership signals a new era for Glenmark Pharma (GNP) GNP’s subsidiary, Ichnos Glenmark Innovation (IGI), has signed an exclusive licensing agreement with AbbVie for its lead investigational asset, ISB-2001.

Glenmark Pharmaceuticals Ltd. has gained 33.85% in the last 3 Months

Glenmark Pharmaceuticals Ltd.

26 May 2025

2004.40

4.46%

EU and lower R&D spending drive 4Q earnings

Buy: Glenmark Pharmaceuticals Ltd.

Target

Motilal Oswal

Glenmark Pharma (GNP) posted a marginally lower-than-expected operating performance in 4QFY25 (2%/5% miss on revenue/EBITDA). Elevated interest outgo and lower other income led to a 16% miss on earnings.

Glenmark Pharmaceuticals Ltd. is trading above its 200 day SMA of 1606.7

Glenmark Pharmaceuticals Ltd.

24 Dec 2024

2004.40

4.46%